{"version":"1.0","provider_name":"Indonesia Tribune","provider_url":"https:\/\/indonesiatribune.com","author_name":"admin","author_url":"https:\/\/indonesiatribune.com\/author\/admin\/","title":"Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series - Indonesia Tribune","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"Ycgd3QdMPm\"><a href=\"https:\/\/indonesiatribune.com\/junshi-biosciences-and-coherus-announce-presentation-of-positive-results-from-choice-01-a-phase-3-clinical-trial-evaluating-toripalimab-in-combination-with-chemotherapy-as-first-line-treatment-for-no\/\">Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/indonesiatribune.com\/junshi-biosciences-and-coherus-announce-presentation-of-positive-results-from-choice-01-a-phase-3-clinical-trial-evaluating-toripalimab-in-combination-with-chemotherapy-as-first-line-treatment-for-no\/embed\/#?secret=Ycgd3QdMPm\" width=\"600\" height=\"338\" title=\"&#8220;Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series&#8221; &#8212; Indonesia Tribune\" data-secret=\"Ycgd3QdMPm\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"\u2013 Toripalimab plus chemotherapy met both primary endpoint of progression free survival and prespecified secondary endpoint of overall survival compared to chemotherapy alone \u2013 \u2013 Data support the use of toripalimab with chemotherapy as first-line treatment for advanced NSCLC patients without EGFR\/ALK mutations \u2013 SHANGHAI, China and\u00a0REDWOOD CITY, Calif., March 15, 2022 (GLOBE NEWSWIRE) \u2014 [\u2026]"}